Pharmaceutical company Dr. Reddy's Laboratories Ltd (BSE:500124) (NSE:DRREDDY) (NYSE:RDY) (NSEIFSC:DRREDDY) on Thursday announced the launch of Toripalimab in India.
Toripalimab is the first and only immuno-oncology drug approved for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). Dr. Reddy's will market it under the brand name Zytorvi in India.
India becomes the third country, after the United States and China, to gain access to this New Biological Entity (NBE). Toripalimab, in combination with standard of care chemotherapy, has shown a 48% reduction in the risk of disease progression or death.
Innovent Biologics' IBI343 receives Breakthrough Therapy Designation in China
OS Therapies reports positive Phase 2b data for OST-HER2 in lung metastatic osteosarcoma
Johnson & Johnson submits New Drug Application for TAR-200 to treat bladder cancer
Creo Medical Group plc launches robotic-guided lung ablation procedures in the UK
Sen-Jam Pharmaceutical receives ethics approval for Australian clinical trial of SJP-001
Phase I/II clinical trial of Ariceum Therapeutics' 225Ac-SSO110 gets US FDA approval
Adaptive Biotechnologies and NeoGenomics partner to expand MRD monitoring for blood cancer
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
Vascarta collaborates with City College of New York to improve efficacy and safety of chemotherapy
bioAffinity Technologies declares successful beta launch of CyPath Lung in Texas
Elicera Therapeutics receives ODD for ELC-100
Anavex reports positive long-term data for blarcamesine in early Alzheimer's disease